Ziftomenib (KOMZIFTI), developed by Kura Oncology in collaboration with Kyowa Kirin, is the first and only once-daily FDA-approved oral menin inhibitor for the treatment of adults with R/R NPM1-mutated AML. Approved by the FDA in November 2025, Ziftomenib received Breakthrough Therapy, Fast Track, Orphan Drug, and Priority Review designations, reflecting its potential to address a significant unmet need in molecularly defined AML. The therapy has differentiated itself from competing menin inhibitors through its convenient once-daily dosing, favorable tolerability profile, and lack of clinically meaningful drug–drug interactions. Although its prescribing information includes a boxed warning for differentiation syndrome, the therapy remains an attractive option for heavily pretreated patients receiving multiple concomitant medications. .

While currently approved as a monotherapy for the relatively small R/R NPM1-Mutant AML population, Kura Oncology is pursuing an aggressive lifecycle expansion strategy to establish ziftomenib in the frontline setting. The agent is being evaluated in registrational studies in combination with intensive induction chemotherapy (7+3) and with venetoclax plus azacitidine, targeting both fit and unfit newly diagnosed AML populations. Encouraging efficacy and manageable safety data from the KOMET-007 program have strengthened confidence in ziftomenib’s frontline potential. As of the data cut-off on April 2026;

Key Efficacy Highlights:

Key Safety Highlights:

• Manageable tolerability with no new safety signals and minimal additive myelosuppression

• No Grade 4 differentiation syndrome or QTc prolongation

• Grade 3 differentiation syndrome was infrequent (3%) and resolved with protocol-specified management

• Grade 3 QTc prolongation occurred in 4% of patients, with only one event considered ziftomenib-related; all cases resolved successfully

KOL insights

“The KOMET-007 update reinforces ziftomenib’s potential in frontline AML, demonstrating deep and durable responses with a manageable safety profile in NPM1-mutated and KMT2A-rearranged disease.”– Expert Opinion

“The depth and durability of responses observed with ziftomenib-based therapy suggest the potential for a transformative treatment approach in AML, with the possibility of reducing the need for allogeneic stem cell transplantation in selected patients.”– Expert Opinion

Conclusion-

AML remains a highly aggressive malignancy, with NPM1-mutated disease representing a key molecular subtype driving the adoption of menin inhibitors. The approval of ziftomenib (KOMZIFTI) has intensified competition in the relapsed/refractory NPM1-Mutant AML market, challenging revumenib's (REVUFORJ) early lead. While REVUFORJ currently benefits from a broader label, emerging data from the KOMET-007 study highlight ziftomenib’s potential to differentiate through high remission rates, deep MRD responses, and durable clinical outcomes in the frontline setting. As the pivotal Phase III KOMET-017 trial progresses, ziftomenib is expected to expand beyond the relapsed/refractory setting and could emerge as a major competitor in frontline AML, with the potential to reshape the evolving menin inhibitor landscape.